



# NIRMALA COLLEGE OF PHARMACY MUVATTUPUZHA



**NATIONAL CONFERENCE**

## **Nano-based Drug Delivery Systems; Recent Developments and Future Prospects**

**7 OCTOBER 2023**

**ASSOCIATING PARTNERS**

**INDIAN PHARMACEUTICAL ASSOCIATION**



**JOURNAL OF INNOVATIONS IN  
APPLIED PHARMACEUTICAL SCIENCES**



**INNOVATION AND  
ENTREPRENEURSHIP  
DEVELOPMENT CENTRE**



**INSTITUTION'S  
INNOVATION  
COUNCIL**  
(Ministry of HRD Initiative)



HOME / ARCHIVES / Volume-8, Issue-3-S, 2023



National Conference on Nano-based Drug Delivery Systems; Recent Developments and Future Prospects conducted By Nirma College of Pharmacy, Muvattupuzha, in association with Indian Pharmaceutical Association on 7 October 2023

RESEARCH ARTICLE(S)

**ASSESSMENT OF PHYSICAL FUNCTIONING IN RHEUMATOID ARTHRITIS PATIENTS AFTER RITUXIMAB THERAPY USING HEALTH ASSESSMENT QUESTIONNAIRE-DISABILITY INDEX**

ANNA MARIA JOY , AKSHARA SHAJI , SHANIYA MATHEW , DR.SUJA ABRAHAM Pages 1-4

[VIEW PDF](#)

**TOXICITY PROFILE OF CHEMOTHERAPY REGIMENS FOR MULTIPLE MYELOMA PATIENTS USING CTCAE CRITERIA**

ANTONY V R, ARPITH ANTONY, HELAN KURIAN, JEEVA ANN JIJU, TIMY THOMAS, JITHIN SUNNY, SUJA ABRAHAM Pages 5-7

[VIEW PDF](#)

**ISOLATION OF EMBELIN FROM EMBELIARIBES BERRIES FOR THE DEVELOPMENT OF TOPICAL ANTI-INFLAMMATORY PREPARATION**

DR. R. BADMANABAN, MARIA S.PADATHIL , HANNA PARVEEN, DONA MERIN JOY, SHAHANA MAJEED, JOYCYMOLS, DR. DHRUBO JYOTI SEN Pages 8-18

[VIEW PDF](#)

**DESIGN AND CHARACTERISATION OF TOPICAL EMULGEL CONTAINING NEEM OIL FOR ITS ANTIDANDRUFF PROPERTIES**

EBY GEORGE, DR DHANISH JOSEPH, ABITHA N JABBAR, KHANSA BEEGAM M A, NIMISHA JOSEPH, MAHIMA FRANCIS, ANJU BOBAN, ANN MARIA ALEX Pages 19-23

[VIEW PDF](#)

**DEVELOPMENT OF IMPLANTABLE DRUG DELIVERY SYSTEM OF EMBELIN FOR THE TREATMENT OF BREAST CANCER**

RINCY. K. K, DR. DHANISH JOSEPH, BINSHA URUMEEES, ANN MARIYA JOSE, ATHIRA ANILAN Pages 24-28

[VIEW PDF](#)

**COMPARATIVE INSILICO DOCKING STUDY INVOLVING ANTAGONISTIC ACTIVITY OF COUMARINDERIVATIVES ON EGFR AND CDK2**

RIYA ANN THOMAS, EVA SARA SUNIL, ANNA ABEL FERNANDEZ, SOORYA ANIL, ANJANA ANTONY, ANN MARIA DAVIS, GODWIN THOMAS, SARANYA T S, GREESHMA SREERAM, DR. ELIZABETH ABRAHAM P Pages 29-35

[VIEW PDF](#)

**ASSESSMENT OF PATIENT KNOWLEDGE, PRACTICE AND ADVERSE EVENTS OF INSULIN ADMINISTRATION AND STORAGE TECHNIQUES IN PATIENTS WITH DIABETES**

ANTRIYA ANNIE TOM, NAMITHA ANTONY, PAVITHRA ASHOK, MUHAMMAD ABDUL KHADIR PS, JUHY JOJO Pages 42-46

[VIEW PDF](#)

**FORMULATION AND EVALUATION OF HERBAL AFTERSHAVE GEL**

CELU MARIYA FRANCIS, RIYA GEORGE, ANASWARA SANKAR, ANCI I J, MANJU MARIA MATHEWS, BADMANABAN R Pages 47-50

[VIEW PDF](#)

**EVALUATION OF ANTIMICROBIAL ACTIVITY OF A HERBAL MIXTURE**

DEEPA JOSE , SINI BABY, SUJJALA SUBASH, GIFTY LAWRENCE, ANEESA ANOOB , LINTA JOSE Pages 59-63

[VIEW PDF](#)

ONLINE SUBMISSION



Online ISSN:2455-5177

CODEN (CAS-USA): JIAPAW

Impact Factor: 5.832

Journal Archived in



KEYWORDS



CURRENT ISSUE

- [JAPS 1.0](#)
- [JAPS 2.0](#)
- [JAPS 3.0](#)

INFORMATION

- [For Readers](#)
- [For Authors](#)
- [For Librarians](#)

[Flag Counter](#)

**EFFICIENT MICROWAVE SYNTHESIS OF COUMARIN DERIVATIVES WITH EVALUATION OF THEIR ANTIOXIDANT AND ANTI-INFLAMMATORY PROPERTIES**

ANZIYA P A, SARANYA T S, ANJALI K, ANJALI KRISHNA, SINI BABY, DIVINE P DANIEL

Pages 124-130

[VIEW PDF](#)

**COSMETIC USE RELATED ADVERSE EVENTS AND NEED FOR COSMETOVIGILANCE**

MERRIN JOSEPH, KARISHMA SHAJI, MAHIN T M, NANDANA P B, KRISHNA DAS

Pages 64-71

[VIEW PDF](#)

**A RETROSPECTIVE STUDY OF CLINICAL PROFILE OF VIPER BITE CASES IN SELECTED HOSPITALS IN CENTRAL KERALA**

ANUMOL SAJU, ANTRIYA ANNIE TOM, ABY PAUL, SWAPNA SAJU, DONA JOHNSON, JESYLN JOE THOMAS, KUTTIKADEN PAGES 72-74  
JOY STEFFI, JOYAL M JOLL

[VIEW PDF](#)

**FORMULATION AND EVALUATION OF HERBAL TOOTHPASTE CONTAINING EUPATORIUM TRIPLINERVISLEAF EXTRACT**

VIDYA PETER, ROSNA BABU , SHERRY SEBASTIAN, ANGEL JAEMON, ANGEL JAEMON, ANAGHA V T, JEEVAN SAJEEV

Pages 36-41

[VIEW PDF](#)

**IN VITRO SCREENING OF ICACINACEOUS PLANTS INDIGENOUS TO KERALA**

DR.ELIZABETH ABRAHAM P, FRINTO FRANCIS, PRADEEP R NAIR, ATHUL RAJ, RAJI RAJAN, ANAMIKA K. NAIR,  
PROF.DR.BADMANABAN.R

Pages 51-58

[VIEW PDF](#)

**FORMULATION AND EVALUATION OF BUCCAL FILM OF AN ANTIHYPERTENSIVE DRUG**

ASHINAA BENEDICT, IRIN ROSE PAUL, DR. MANJU MARIA MATHEWS, DR. BADMANABAN R

Pages 75-80

[VIEW PDF](#)

**A PROSPECTIVE SURVEY TO ASCERTAIN THE SYMPTOMS, HEALTH ISSUES AND SUBSEQUENT OTC MEDICATION USAGE DURING MENSTRUATION AMONG COLLEGE STUDENTS**

MINTU GEORGE, ANAGHA MELBIN, MARY PAUL DOMINIC, RESHMA DOMINIC, AYSHA SAJA P.S, JOBIN KUNJUMON  
VILAPURATHU

Pages 81-84

[VIEW PDF](#)

**A CROSS SECTIONAL STUDY TO ANALYSE THE ADR REPORTED IN A HOSPITAL DURING THE PAST THREE YEARS**

SANGEETHA SUKUMARAN, VARSHA ELIZABETH JOBY, AMALA JOSEPH, APARNA JESTIN, JITHIN N P, SUMAYYA B  
MUHAMMED, SUNU SEBASTIAN, JOBIN KUNJUMON VILAPURATHU

Pages 85-89

[VIEW PDF](#)

**FORMULATION AND EVALUATION OF PREUNGUAL DELIVERY SYSTEM CONTAINING EUGENOL FOR THE TREATMENT OF ONYCHOMYCOSIS**

MINI ELIAS, FLOWERLET MATHEW, GOURISREE T, ANILA RAJAN, ASHLY DAVIS

Pages 90-94

[VIEW PDF](#)

**FORMULATION AND EVALUATION OF FLOATING CONTROLLED DRUG DELIVERY OF ANTI-ULCER DRUG LOADED MICROBALLOONS**

BINDUMOL K C, FLOWERLET MATHEW, SHALOM SUNIL, ANGEL JOSE

Pages 95-100

[VIEW PDF](#)

**PREPARATION AND EVALUATION OF FLOATING DRUG DELIVERY SYSTEM (FDSD) CONTAINING AN ANTIVIRAL DRUG**

TEENA MOHAN, MARIYA SUNNY, MANJU MARIA MATHEWS, BADMANABAN R

Pages 105-109

[VIEW PDF](#)

**FORMULATION AND EVALUATION OF CONTROLLED POROSITY ORAL OSMOTIC PUMP TABLETS OF FUROSEMIDE**

TEENA CHACKOCHEN THEKKAL, REBA RENJU, MANJU MARIA MATHEWS, BADMANABAN R

Pages 110-113

[VIEW PDF](#)

**FORMULATION AND EVALUATION OF TOPICAL GELS INCORPORATED WITH SOLID DISPERSIONS OF AN ANTIINFLAMMATORY DRUG**

SETHU LEKSHMI, THERASE JOSE, MANJU MARIA MATHEWS, BADMANABAN R


Pages 114-119

[VIEW PDF](#)

**IN VITRO ANTI-BACTERIAL SCREENING OF DRYNARIYA QUERCIFOLIA**

ASHNA T, LINS MARY JOY, SIYARA ANTONY, SINDU T J, SHEEBA MOL P, SHUJI T S, SOUMYA K GEORGE

Pages 120-123

 [VIEW PDF](#)

**CASE REPORT(S)**

**GUILLAIN-BARRE SYNDROME: A PAEDIATRIC CASE SCENARIO IN A TERTIARY CARE HOSPITAL AT SOUTHERN INDIA**

NEVIN JOSEPH, ALFIN BABY, ELDHOSE ELIAS GEORGE, GOPIKRISHNAN T.S, MERRIN JOSEPH

Pages 101-104

 [VIEW PDF](#)

[Announcements](#) || [Editorial Board](#) || [Indexing](#) || [Contact](#)

The publication is licensed under a [Creative Commons License \(CC BY-NC\)](#). [View Legal Code](#)

Copyright © 2023, JIAPSONline



# Journal of Innovations in Applied Pharmaceutical Science [JIAPS]

Content available at: [www.saap.org.in](http://www.saap.org.in) ISSN: 2455-5177



## COMPARATIVE INSILICO DOCKING STUDY INVOLVING ANTAGONISTIC ACTIVITY OF COUMARINDERIVATIVES ON EGFR AND CDK2

Riya Ann Thomas<sup>1</sup>, Eva Sara Sunil<sup>1</sup>, Anna Abel Fernandez<sup>1</sup>, Soorya Anil<sup>1</sup>, Anjana Antony<sup>1</sup>, Ann Maria Davis<sup>1</sup>, Godwin Thomas<sup>1</sup>, Saranya T S<sup>\*1</sup>, Greeshma Sreeram<sup>1</sup>, Elizabeth Abraham P<sup>2</sup>

<sup>\*1</sup>Dept of Pharmaceutical Chemistry, Nirmala College of Pharmacy, Muvattupuzha, Kerala

<sup>2</sup>Dept of Pharmacology, Nirmala College of Pharmacy, Muvattupuzha, Kerala

### Article History

Received: 07-10-2023

Revised: 27-10-2023

Accepted: 13-10-2023

**Keywords:** Coumarin, EGFR, CDK2, AutoDock4, Piroxicam.



### Abstract

Epidemiological evidence suggests that about 25% of cancer occurs due to chronic inflammation, thus it is clear that cancer and inflammation are related. Piroxicam is the one of the drug that is used in the treatment of both cancer and inflammation, but it is having some side effects like constipation, blurring of vision, skin rashes etc. Coumarin is having both anti-inflammatory and anti-cancer activity so the purpose of this study is to screen the best target among EGFR and CDK2. Docking analysis was carried out using AutoDock4. From the study it was found that EGFR showed better result compare to CDK2. Also methyl substitution at 8<sup>th</sup> position and chlorine substitution at 5<sup>th</sup> position of coumarin showed better activity than standard drug piroxicam and phytoconstituents *isofraxidin* and *scopoletin*.

This article is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License.

Copyright © 2023 Author[s] retain the copyright of this article.



### \*Corresponding Author

Saranya T S

<https://doi.org/10.37022/jiaps.v8i3-S.518>

### Production and Hosted by

[www.saap.org.in](http://www.saap.org.in)

### Introduction

Inflammation is the body's response to internal and external environment in order to eliminate unwanted agents from body and thus restore the tissue physiology. Chronic inflammatory conditions in selected organs increase the risk of cancer. EGFR (epidermal growth factor) plays an important role in inflammation as well as cancer. EGFR belongs to HER family of receptors, in which EGFR is activated by binding to EGF which cause receptor dimerization and tyrosine autophosphorylation leading to cell proliferation [4, 5].

CDK2 belongs to family protein kinases, it is also known as cell division protein kinase-2. Initially it was discovered for its action in regulating cell cycle later it was found that inhibition of this protein lead to variety of action like anti-cancer, anti-inflammatory action etc. CDKs require cyclin for its activation. CDK2 inhibitors produce anti-inflammatory activity by inhibiting MAPK, NF-Kb and PI3K signalling pathways. In the case of cancer CDK2 inhibitors prevent the stimulation of the cell to enter in to s phase of cell cycle and reduce cell proliferation [6, 7]

Computer -aided drug design (CADD) uses computational chemistry to discover, enhance or to study drug and related biologically active molecules. The problems associated with the conventional method of drug designing are overcome by the CADD. Two methods in CADD are structural based and ligand based drug design. Structural based drug design depends on the three dimensional structure of biological target whereas ligand based drug design depends on molecules that bind to biological target [8]. In this work we have carried out the study on coumarin derivatives and the standard drug selected for the study was piroxicam [9]. The phytoconstituents selected for the study are *scopoletin* and *isofraxidin* [10].

### Materials and methods

Twenty eight lead molecules were designed by using chemsketch by giving substitution on 5th, 6th, 7th and 8th position of the compound having coumarin nucleus as shown in fig: 1




Fig.13-[(2E)-3-phenylprop-2-enoyl]-2H-chromen-2-one

### Selection of target

#### Primary and Secondary Structure Analysis

Targets were selected from PDB after carrying out the primary and secondary structure analysis. PDB is a crystallographic database or the three-dimensional structural data of large biomolecules such as proteins and nucleic acids.

Primary structure analysis was done by using protparam, which computes various physico-chemical properties from protein sequences. Various parameters studied using protparam are molecular weight, theoretical pi, half-life, GRAVY, aliphatic index, instability index [11, 12], results are given in table 1 and 2. Secondary structure analysis was done using sopma, which indicates whether a given amino acid lies in a helix, strand or coil, results are computed in table 3 and 4.

**Table 1. Primary Structure Analysis of EGFR**

SL.NO	PDB ID	Molecular weight	Theoretical pi	Half life (hr.)	Aliphatic index	Extinction coefficient m-1cm-1	GRAVY	Instability index
1	1M14	37827.7	5.67	30	94.26	52745	-0.221	43.79
2	1M17	37827.7	5.67	30	94.26	52745	-0.221	43.49
3	1XKK	40269	5.88	30	91.11	52725	-0.315	42.52
4	2GS2	37516.4	5.59	30	95.12	52745	-0.208	43.47
5	2GS6	41363.4	5.10	30	90.27	54360	-0.305	45.47
6	2JSF	37257.1	5.59	30	95.69	52745	-0.220	44.04
7	2J6M	37257.1	5.59	30	95.69	52745	-0.220	44.04
8	2ITY	3707.9	5.70	4.4	96.28	52745	-0.210	44.48
9	2ITX	37257.1	5.59	30	95.69	52745	-0.220	44.04
10	2ITW	37257.1	5.59	30	95.69	52745	-0.220	44.04

**Table.2 Primary structure analysis of CDK2**

SL.NO	PDB ID	Molecular weight	Theoretical pi	Half life (hr.)	Aliphatic index	Extinction coefficient m-1cm-1	GRAVY	Instability index
1	2KW6	7421.4	9.43	30	81.23	2980	-0.729	56056
2	2M1L	7631.7	9.42	1.9	70.87	2980	-0.577	55.48

**Table.3 Secondary structure analysis of EGFR**

SL.NO	PDB ID	Alpha helix	Extended strand	Beta turn	Random coil
1	1M14	157	57	35	81
2	1M17	157	57	35	84
3	1XKK	157	62	33	100
4	2GS2	157	55	32	86
5	2GS6	157	55	32	86
6	2JSF	157	55	32	83
7	2J6M	157	55	32	83
8	2ITY	157	55	32	81
9	2ITX	157	55	32	83
10	2ITW	157	55	32	83

**Table.4 Secondary structure analysis of CDK2**

SL.NO	PDB ID	Alpha helix	Extended strand	Beta turn	Random coil
1	2KW6	50	1	1	13
2	2M1L	45	4	3	17

From primary and secondary structure analysis parameters like half-life and random coil coefficient were considered for the selection of targets. Targets that show highest value in both the parameters were selected as targets for docking analysis.

**Preparation of ligands**

The ligands were designed from chemsketch and saved in PDB format, their smiles notation were also obtained from same. Chemsketch is chemically intelligent drawing interface software developed by Advanced Chemistry Department.

**Validation of ligands**

Drug likeness is a parameter that helps to determine the various molecular properties of compound in conjugation with the pharmacophore. This was determined using an online software Molinspiration, using this software molecular properties based on Lipinski rule of five and drug ADME profile was also checked. Various parameter are determined which include log p, number of hydrogen bond donor or acceptors which is necessary for eliminating non-drug like molecules[13].The results are compiled in table 6 and 7.

**Docking study:****Molecular docking**

Docking is a method, which predicts the preferred orientation of one molecule to a second when bound to each other to form a stable complex. In this study docking was carried out using AutoDock4. After the energy minimisation of ligand and protein, water molecules are removed and docked with the lead molecules to get the docking score. The results are computed in table 8 and 10. The selected targets were also docked with the phytoconstituents having coumarin nucleus and the standard drug used in the treatment of inflammation as well as the cancer and the results are computed in table 9 and 11.

**Results and Discussion****Table.6 Analysis of Lipinski rule of five for novel proposed analogues of coumarin**

Sl.No	Name of the compound	Molecular Weight	No.of Hba	No.of Hbd	C log p	No of Rot.b	No.of Violations
1	5-chloro-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromen-2-one	310.74	3	0	4.45	3	0
2	6-chloro-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromen-2-one	310.74	3	0	4.47	3	0
3	7-chloro-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromen-2-one	310.74	3	0	4.47	3	0
4	8-chloro-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromen-2-one	310.74	3	0	4.45	3	0
5	5-bromo-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromen-2-one	355.19	3	0	4.58	3	0
6	6-bromo-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromen-2-one	355.19	3	0	4.6	3	0
7	7-bromo-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromen-2-one	355.19	3	0	4.6	3	0
8	8-bromo-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromen-2-one	355.19	3	0	4.58	3	0
9	5-fluoro-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromen-2-one	294.28	3	0	2.98	3	0
10	6-fluoro-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromen-2-one	294.28	3	0	3.96	3	0
11	7-fluoro-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromen-2-one	294.28	3	0	3.96	3	0
12	8-fluoro-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromen-2-one	294.28	3	0	3.93	3	0
13	5-hydroxy-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromen-2-one	292.29	4	1	3.55	3	0
14	6-hydroxy-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromen-2-one	292.29	4	1	3.31	3	0
15	7-hydroxy-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromen-2-one	292.29	4	1	3.31	3	0
16	8-hydroxy-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromen-2-one	292.29	4	1	3.55	3	0
17	5-methyl-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromen-2-one	290.32	3	0	4.22	4	0

The results for validation of ligands shows that values of all twenty eight compounds based on molecular weight is less than 500 Daltons, no. of hydrogen bond donors and acceptors are below 5 and 10, partition coefficient is within the limit, this shows that there is no violation of Lipinski rule of 5.

Table.7 Bioactivity results of proposed analogues of coumarin

Sl.No	GPCR Ligand	Ion channel modulator	Kinase Inhibitor	Nuclear Receptor Ligand	Protease Inhibitor	Enzyme Inhibitor
1	-0.42	-0.49	-0.54	-0.23	-0.37	-0.12
2	-0.4	-0.53	-0.56	-0.22	-0.34	-0.11
3	-0.37	-0.48	-0.62	-0.19	-0.35	-0.08
4	-0.49	-0.67	-0.6	-0.21	-0.35	-0.09
5	-0.44	-0.66	-0.5	-0.27	-0.41	-0.13
6	-0.54	-0.65	-0.6	-0.38	-0.47	-0.17
8	-0.21	-0.68	-0.66	-0.3	-0.4	-0.1
9	-0.33	-0.51	-0.42	-0.14	-0.33	-0.08
10	-0.36	-0.54	-0.51	-0.16	-0.35	-0.07
11	-0.29	-0.47	-0.47	-0.22	-0.31	-0.06
12	-0.41	-0.49	-0.5	-0.07	-0.34	-0.03
13	-0.37	-0.45	-0.52	-0.14	-0.26	-0.03
14	-0.33	-0.48	-0.46	-0.02	-0.31	-0.01
15	-0.36	-0.51	-0.5	-0.03	-0.33	0
16	-0.37	-0.47	-0.5	-0.13	-0.23	0.06
17	-0.46	-0.75	-0.55	-0.21	-0.42	-0.14
18	-0.45	-0.61	-0.6	-0.24	-0.38	-0.14
19	-0.44	-0.61	-0.62	-0.26	-0.4	-0.15
20	-0.51	-0.71	-0.64	-0.22	-0.46	-0.12
21	-0.37	-0.6	-0.54	-0.14	-0.32	-0.07
22	-0.35	-0.5	-0.58	-0.15	-0.26	-0.07
23	-0.35	-0.49	-0.6	-0.16	-0.28	-0.07
24	-0.32	-0.66	-0.59	-0.14	-0.4	-0.09
25	-0.43	-0.61	-0.44	-0.04	-0.45	-0.11
26	-0.46	-0.54	-0.55	-0.12	-0.45	-0.12
27	-0.46	-0.54	-0.57	-0.14	-0.46	-0.12
28	-0.42	-0.62	-0.51	-0.14	-0.47	-0.13

**Docking Analysis**

Docking scores for coumarin derivatives against EGFR is given in table.8 and the docking score for phytoconstituents having coumarin pharmacophore is given in table.9

Table.8 Docking scores for novel proposed analogues of coumarin against EGFR

SL.No	Substitution	Docking Score (kcal/mol)
1	5-chloro-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromen-2-one	-6.5563
2	6-chloro-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromen-2-one	-9.02525
3	7-chloro-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromen-2-one	-9.50823
4	8-chloro-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromen-2-one	-9.07289
5	5-bromo-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromen-2-one	-6.97647
6	6-bromo-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromen-2-one	-9.50701
7	7-bromo-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromen-2-one	-5.73848
8	8-bromo-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromen-2-one	-6.57724



9	5-fluoro-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromen-2-one	-8.00148
10	6-fluoro-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromen-2-one	-9.38909
11	7-fluoro-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromen-2-one	-6.80107
12	8-fluoro-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromen-2-one	-9.5179
13	5-hydroxy-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromen-2-one	-7.57281
14	6-hydroxy-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromen-2-one	-9.35864
15	7-hydroxy-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromen-2-one	-9.79347
16	8-hydroxy-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromen-2-one	-9.36727
17	5-methyl-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromen-2-one	-7.24347
18	6-methyl-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromen-2-one	-8.28572
19	7-methyl-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromen-2-one	-9.48994
20	8-methyl-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromen-2-one	-10.0089
21	5-ethyl-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromen-2-one	-8.07182
22	6-ethyl-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromen-2-one	-8.92836
23	7-ethyl-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromen-2-one	-6.9066
24	8-ethyl-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromen-2-one	-6.90994
25	2-oxo-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromene-5-carbaldehyde	-8.78985
26	2-oxo-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromene-6-carbaldehyde	-7.6281
27	2-oxo-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromene-7-carbaldehyde	-9.69306
28	2-oxo-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromene-8-carbaldehyde	-8.43019

**Table.9 Docking scores of phytoconstituents having coumarin pharmacophore against EGFR**

SL.NO	Phytoconstituents	Docking score (kcal/mol)
1	<i>Isofraxidin</i>	-6.608
2	<i>Scopoletin</i>	-6.219

Docking score for coumarin derivatives against CDK2 is given in table.10 and the docking score of phytoconstituents against CDK2 is given in table.11

**Table.10 Docking scores for novel proposed analogues of coumarin against CDK2**

SL.No	Substitution	Docking Score (Kcal/mol)
1	5-chloro-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromen-2-one	-9.08063
2	6-chloro-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromen-2-one	-7.17984
3	7-chloro-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromen-2-one	-6.23813
4	8-chloro-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromen-2-one	-6.17164
5	5-bromo-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromen-2-one	-7.86579
6	6-bromo-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromen-2-one	-8.25594
7	7-bromo-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromen-2-one	-7.2153
8	8-bromo-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromen-2-one	-6.37073

9	5-fluoro-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromen-2-one	-6.24518
10	6-fluoro-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromen-2-one	-6.05296
11	7-fluoro-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromen-2-one	-6.63018
12	8-fluoro-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromen-2-one	-6.2655
13	5-hydroxy-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromen-2-one	-7.59957
14	6-hydroxy-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromen-2-one	-7.93164
15	7-hydroxy-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromen-2-one	-6.27102
16	8-hydroxy-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromen-2-one	-6.91668
17	5-methyl-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromen-2-one	-6.24409
18	6-methyl-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromen-2-one	-6.40065
19	7-methyl-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromen-2-one	-6.12575
20	8-methyl-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromen-2-one	-6.45836
21	5-ethyl-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromen-2-one	-7.10218
22	6-ethyl-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromen-2-one	-8.49001
23	7-ethyl-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromen-2-one	-8.49001
24	8-ethyl-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromen-2-one	-6.01942
25	2-oxo-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromene-5-carbaldehyde	-6.59915
26	2-oxo-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromene-6-carbaldehyde	-7.13007
27	2-oxo-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromene-7-carbaldehyde	-6.66722
28	2-oxo-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromene-8-carbaldehyde	-6.12156

**Table.11 Docking scores of phytoconstituents having coumarin pharmacophore against CDK2**

SL.NO	Phytoconstituents	Docking score (kcal/mol)
1	<i>Isofraxidin</i>	-6.369
2	<i>Scopoletin</i>	-6.03

Docking analysis of coumarin derivatives with methyl substitution at 8th position shows highest score against EGFR.(Fig.2)




Fig.2 8-methyl-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromen-2-one

Docking analysis of coumarin derivatives with chlorine substitution at the 5th position shows highest score against CDK2.(Fig.3)




Fig.3 5-chloro-3-[(2E)-3-phenylprop-2-enoyl]-2H-chromen-2-one

Among twenty eight compounds fifteen of them show good score against EGFR and seven of them show good score against CDK2 as compared to the standard drug piroxicam.

## Conclusion

Docking studies conducted in coumarin derivatives against CDK2 and EGFR for anti-inflammatory as well as anti-cancer activities was successful and it was found that among the two targets, EGFR showed good affinity towards the fifteen proposed analogues, and in that methyl substitution at the 8th position of the coumarin scaffold showed the best docking score as compared to the standard drug piroxicam and the two phytoconstituents whereas CDK2 showed good affinity towards seven proposed analogues among them chlorine substitution at 5th position shows highest score as compared to standard and two phytoconstituents. From this study we came to a conclusion that, among twenty eight ligands the best ligand for anti-inflammatory and anti-cancer activity was obtained when the coumarin derivative is substituted with methyl group at 8th position and chlorine atom at 5th position.

## Reference

1. Wallace B. Morrison. Inflammation and cancer: A comparative view. International Journal of Veterinary Medicine.2012, 26, 18-31.
2. P.K Jain, Himashu Joshi. Coumarin: chemical and pharmacological profile. Journal Of Applied Pharmaceutical Science.2012, 2, 6,236-40.
3. Aoife Lacy and Richard O' Kennedy. Studies on Coumarin and Coumarin –Related compounds to determine their therapeutic role in the treatment of cancer. Current Pharmaceutical Design .2004, 10, 3797-3811.
4. Nicola Normanno, Antonella De Luca, Caterina Bianco et.al.Epidermal Growth Factor receptor signalling in cancer.Gene.2006,366,1,2-12.
5. B.Rude Voldborg, Damstrup, M.Spang- Thomsen, H.Skovgaard Poulsen. Epidermal Growth Factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Annals of Oncology.1997, 8, 12, 1197-1206.
6. Arun kumar V.A, Keshav Mohan. Insights into binding of potential antitumour quinoxaline analogues against cyclin dependent kinase 2 using docking studies. Journal of chemical, biological and physical sciences.2012, 4, 2, 2419-274.
7. Sunil H Ganatra, Amita S Suchak.Inhibition Studies of Naturally Occuring Terpene based compounds with Cyclin – Dependent kinase 2 enzymes .Journal of computer Science system biology.2012, 5, 2, 68-73.
8. Susmi M.S, Revathy S Kumar, Sreelakshmi V et.al. A computational approach for identification of phytochemicals for targeting and optimizing the inhibitors of heat shock proteins. Research Journalof Pharmacy and Technology.2015, 8, 9, 1199-1204.
9. Elizabet R.Rayburn, Scharri J.Ezell and Ruiwen Zhang. Anti –inflammatory agents for cancer therapy. Journal of molecular cell pharmacology.2009, 1, 1, 29-43.
10. S.Mirunalini, M. Krishnaveni. Coumarin: A Plant derived polyphenol with wide biomedical applications. International Journal of pharma Tech Research.2011, 3, 3, 1693-96.
11. Pradeep N.V, Anupama, Vidyashree K.G et.al. In silico characterisation of industrial important cellulases using computational tools .Advances in Life Science and Technology.2012, 4, 8-15.
12. Reshma Thomas, R.Hari, Josna Joy et.al. In silico docking approach of coumarin derivatives as an aromatase antagonist. Research journal of pharmacy and technology.2013, 8, 12, 1673-78
13. Sekhar A S, Basker V, Saranya T S, in silico approach of apoptosis inducing ability of different indole derivatives by interaction with caspase 9, 2016, 40, 2, 92-102